Stephan Forstot, MD
Ophthalmology · Littleton, CONPI 1881687432
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Amgen at 29.5% of the total. Reporting peaked in 2021 at $3,871 and has fallen 97.0% since, to $115 in 2025.
Across 71 payments — averaging $97.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Eyevance Pharmaceuticals LLC$2K
- Kala Pharmaceuticals, Inc.$1K
- AbbVie$622
- Sun Pharmaceutical Industries Inc.$265
- Aerie Pharmaceuticals, Inc.$192
- plus $769 from 14 others
Across 22 payments — averaging $14,649 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$297K
- Kala Pharmaceuticals, Inc.$21K
- Oyster Point Pharma, Inc.$5K
What the payments were for
- Consulting fees$2,55037%
- Speaking & faculty fees$2,00029%
- Food & beverage$2,37634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $2,043 |
| Eyevance Pharmaceuticals LLC | 11 | $1,660 |
| Kala Pharmaceuticals, Inc. | 5 | $1,374 |
| AbbVie(2 entities) | 23 | $622 |
| Sun Pharmaceutical Industries Inc. | 5 | $265 |
| Aerie Pharmaceuticals, Inc. | 4 | $192 |
| Harrow Eye, LLC | 2 | $180 |
| Dompe US, Inc. | 2 | $159 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $150 |
| Ocular Therapeutix, Inc. | 2 | $48 |
| Alcon | 1 | $35 |
| Biotissue Holdings Inc. | 2 | $33 |
| Glaukos Corporation | 2 | $33 |
| Shire North American Group Inc | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
| Rxsight Inc | 1 | $24 |
| Sight Sciences, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,926 in reported general payments places this provider in the 85th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 78 | $109,700 |
| Cyclosporine | 24 | $22,463 |
| Fluorometholone | 193 | $18,117 |
| LumiganBimatoprost | 22 | $11,589 |
| MieboPerfluorohexyloctane/Pf | 11 | $11,030 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $7,979 |
| Prednisolone Acetate | 103 | $6,517 |
| Travoprost | 38 | $5,636 |
| Loteprednol Etabonate | 12 | $4,433 |
| Brimonidine Tartrate | 128 | $4,344 |
| Latanoprost | 261 | $2,783 |
| MoxifloxacinMoxifloxacin Hcl | 39 | $2,680 |
| ZioptanTafluprost/Pf | 14 | $2,128 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 71 | $1,745 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $1,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $622 | $129,269123 claims |
| Bausch & Lomb Americas Inc.Miebo | $25 | $11,03011 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $150 | $4,43312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Littleton
- Robert FishLittleton$12K
- Gregory KouyoumdjianLittleton$4K
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.